Phase 3 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children aged 12 to 17 years old.
- Boys or girls.
- People who have had ongoing nerve pain for more than 3 months after surgery or an injury, even after receiving recommended treatments.
- People whose nerve pain has been assessed using a specific scoring tool (called DN4) and reached a qualifying score, and where the pain is located in an area connected to the nerve affected by the surgery or injury.
- People whose treatment, check-ups, and follow-up appointments can all take place at one of the official study centres.
- Girls who could become pregnant must be using an approved method of contraception throughout the study and for 48 hours after the last treatment patch. Approved methods include abstinence, progestogen-only oral contraception (where ovulation is not the main thing being blocked), male or female condoms (with or without spermicide), a cap, diaphragm, or sponge used with spermicide, or a combination of these barrier methods. A negative pregnancy test within 7 days before the first treatment patch is also required (confirm with trial site).
Who may not be able to join:
- People with an intellectual disability that would prevent them from completing the required pain questionnaires.
- People who do not have sufficient command of the French language to complete the study questionnaires and assessment tools.
- People whose parents or guardians refuse to give consent.
- People who object to taking part themselves.
- People who have an existing neurological disease (a condition affecting the brain or nerves).
- People currently receiving a treatment known to be harmful to nerves.
- People who have previously been treated with capsaicin (the active ingredient used in this trial).
- People who have a skin wound, sore, or lesion on the area where the pain is located.
- People whose painful area is on the face, above the hairline on the scalp, or close to any mucous membranes (such as the mouth, nose, or eyes).
- People who have a known allergy or sensitivity to the active ingredient or any other components of the study treatment (Qutenza patch).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Philippe J LE MOINE, MD, CHU of Brest
Phone: +33298223956
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The change in Neuropathic Pain Symptom Inventory score (NPSI)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.